EP1868604A2 - Regulation de la synthese des proteines par inhibition de l'interaction eif4e-eif4g - Google Patents

Regulation de la synthese des proteines par inhibition de l'interaction eif4e-eif4g

Info

Publication number
EP1868604A2
EP1868604A2 EP06719064A EP06719064A EP1868604A2 EP 1868604 A2 EP1868604 A2 EP 1868604A2 EP 06719064 A EP06719064 A EP 06719064A EP 06719064 A EP06719064 A EP 06719064A EP 1868604 A2 EP1868604 A2 EP 1868604A2
Authority
EP
European Patent Office
Prior art keywords
compound
formula
eif4e
phenyl
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP06719064A
Other languages
German (de)
English (en)
Other versions
EP1868604B1 (fr
Inventor
Gerhard Wagner
Michael Chorev
Nathan John Moerke
Huseyin Aktas
Jose Halperin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard College
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of EP1868604A2 publication Critical patent/EP1868604A2/fr
Application granted granted Critical
Publication of EP1868604B1 publication Critical patent/EP1868604B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A61K31/515—Barbituric acids; Derivatives thereof, e.g. sodium pentobarbital
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Definitions

  • eIF4E binds the 7- methylguanosine cap structure found at the 5' ends of most messenger RNAs. Its binding partner eIF4G, a scaffold protein, provides a docking site for other initiation factors, including the RNA helicase eIF4A.
  • eIF4E, eIF4G, and eIF4A forms a ternary complex referred to as eIF4F.
  • this complex recruits the 4OS ribosomal subunit to the 5' end of the mRNA molecule as a result of the interaction of eIF3 with eIF4G, followed by scanning of the 4OS subunit to the initiation codon where it joins with the 60S subunit.
  • This process is facilitated by eIF4A, with the requirement for its helicase activity being directly proportional to the amount of secondary structure in the 5' UTR that must be melted for scanning to occur.
  • the invention features inhibitors of translation initiation that selectively suppress synthesis of growth factors and oncogene products.
  • the invention includes a number of small molecule inhibitors of the protein-protein interaction between the eukaryotic translation initiation factors eIF4E and eIF4G.
  • the molecular mass of the inhibitory compounds is 600 daltons or less, e.g., 500 daltons, 400 daltons, 300 daltons, 200 daltons, 100 daltons.
  • the inhibitor is not a peptide or proteinaceous in nature.
  • compounds of the invention include those that modulate eIF4E/eIF4G interactions and have the formula
  • R 1 is a hydrazone thiazole moiety of the structure
  • R 2 is hydrogen, hydroxyl, CN, CF 3 , CO 2 H, SO 3 H, PO 3 H 2 , SO 2 R, SO 2 NHR, SONH 2 , CONH 2 , CONHR and NHCOR, or a nitro group present in one, two, or three locations on the ring to which it is attached; where R is an alkyl of 1-4 carbones or aryl.
  • R is lower alkyl, e.g., C1-C4, or aryl.
  • R4 is hydrogen, hydroxyl or lower hydroxyalkyl, carboxyl, a lower alkyl ester, e.g., o C-OMe 3 or oxygen (in which case the dotted bond is present, i.e., forming a carbonyl group); tetrazole, SO 3 H, or PO 3 H 2 ; - R 5 is N (in which case the dotted bond is present), NH, or carbonyl; and
  • R 6 is NH or carbonyl.
  • R 4 is desirably a carboxylate group or a pharmaceutically acceptable salt thereof;
  • R 5 is desirably N; and
  • R 6 is desirably NH.
  • R 5 and R 6 may desirably respectively be carbonyl and CH 2 ; CH 2 and carbonyl; NH and CH 2 ; or CH 2 and NH. Examples of compounds of the invention include the following:
  • the compound is EGI-I, referred herein as compound 154300, ICCB
  • the present invention also features a method of inhibiting cap-dependent protein synthesis in a cell by contacting the cell with one or more of the compound described above.
  • This inhibition in turn causes apoptosis, which results from the down-regulation of growth- promoting proteins as well as the up-regulation of apoptosis-promoting proteins and IRES- dependent proteins (e.g., Apaf-1, c-myc, XIAP, and DAP5).
  • IRES- dependent proteins e.g., Apaf-1, c-myc, XIAP, and DAP5
  • the compounds described herein bind a hydrophobic groove of eIF4E formed by the polypeptide segments 68 - 84 and 120-140 of human eIF4E (SEQ ID NO: 1).
  • the compounds inhibit the binding of eIF4G to eIF4E by blocking the eIF4G-binding site on eIF4E, displacing eIF4G from eIF4E by competitive binding or both.
  • the different compounds investigated bind at slightly different but adjacent positions within the groove formed by segments 37-39, 68 - 84, and 120-140.
  • EGI-I Compound 154300
  • compound 600628 binds at an adjacent site near residues V69, F72, W73 and Y76.
  • the adjacent binding sites also include
  • the N-terminal segment that is eliminated contains a RAIP motif which is needed to start phosphorylation.
  • the truncated form of 4E-BP1 binds tightly to eIF4E but is not efficiently phosphorylated.
  • the ectopic expression of eIF4E protects cells from apoptosis whereas the overexpression of 4E-BP1 can induce apoptosis in transformed cells.
  • Treatment of cultured cells with synthetic peptides containing the eIF4E-binding motif fused to a penetratin sequence has been shown to induce apoptosis.
  • adjacent to is meant within 1, 2, 3, 4, or 5 positions upstream (NH 2 ) or downstream (COOH) of the reference amino acid in the reference sequences.
  • the invention further features a method of identifying a composition that reduces protein synthesis.
  • This method involves contacting an eIF4E polypeptide with a candidate compound and a eIF4G polypeptide and detecting a reduction in the level of eIF4E/eIF4g interaction in the presence of the compound compared to that in the absence of the compound.
  • a reduction of eIF4E/eIF4g interaction indicates that the compound reduces protein synthesis.
  • the eIF4E polypeptide comprises residues 68-84 of SEQ ID NO:1; residues 120-140 of SEQ ID NO:1; residues 37-39 of SEQ ID NO:1; or residues 37-39, 68-84 and 120-140 of SEQ ID NO:1.
  • the eIF4E polypeptide can also include at least 6 contiguous residues of SEQ ID NO:1, such that the polypeptide includes at least one of the following residue: residue 37, 38, 39, 69, 72, 73, 76, 81, 82, 83, 127, 131, 135, and 138 of SEQ ID NO:1.
  • the eIF4E polypeptide is murine or human.
  • the IF4E polypeptide can also include a Y(X) 4 L ⁇ motif, where X is any amino acid and where ⁇ is hydrophobic amino acid.
  • the method is carried out by detecting binding of the candidate compound to an eIF4E polypeptide alone or an eIF4g polypeptide alone.
  • the latter method is carried out in fluid phase or with either the initiation factor or candidate compound immobilized on a solid support.
  • the method features a method of identifying a composition that preferentially inhibits tumor cell proliferation, that involves contacting a cell with any of the compounds described herein.
  • the detection of a reduction in the level of proliferation of a tumor cell in the presence of the compound compared to a non-tumor cell in the presence of this compound indicates that the compound preferentially inhibits tumor cell proliferation.
  • Tumor cell proliferation is preferably at least 10% more compared to non-tumor cells and if desired, the compound is a 2- thiazolyl hydrazone.
  • the compounds described herein are useful to inhibit protein synthesis thereby inhibiting proliferation of a cell such as a tumor cell or an abnormal cell (benign or malignant cell).
  • An abnormal cell is a cell having an increased proliferation index, a decreased apoptotic index, or both relative to a normal non-cancerous cell.
  • the compounds preferentially or selectively inhibit tumor cell growth compared to normal cell growth.
  • protein synthesis and/or cell proliferation is inhibited at least 10%, 25%, 50%, 75%, 100%, and up to 5- fold, 10-fold and more in tumor cells compared to non-tumor cells.
  • the method is carried out by administering to a patient in need thereof a pharmaceutical composition containing the inhibitory compound.
  • the patient or animal to be treated is identified as one that has a tumor cell containing an increased level of a cap-dependent translation initiation factor compared to the level in a normal non-tumor cell.
  • the patient is diagnosed as having a tumor or abnormal proliferating cells which is characterized by an increased amount of a cap-dependent translation factor compared to the level in a normal non-tumor cell.
  • the tumor cell contains an aberrantly high amount of eIF4E and/or eIF4G.
  • Such tumor types include tumors of the lung, breast, skin, bone, head (neurological tissues such as brain and spinal cord), neck, bladder, colon, prostate, ovaries, uterus, cervix, larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal gland, kidney, bronchi, liver, gastrointestinal tract, lymphomas, and neuroblastomas.
  • aryl includes groups with aromaticity, including 5- and 6- membered “unconjugated”, or single-ring, aromatic groups that may include from zero to four heteroatoms, as well as “conjugated”, or multicyclic, systems with at least one aromatic ring.
  • aryl groups include benzene, phenyl, pyrrole, furan, thiophene, thiazole, isothiazole, imidazole, triazole, tetrazole, pyrazole, oxazole, isooxazole, pyridine, pyrazine, pyridazine, and pyrimidine, and the like.
  • aryl includes multicyclic aryl groups, e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
  • multicyclic aryl groups e.g., tricyclic, bicyclic, e.g., naphthalene, benzoxazole, benzodioxazole, benzothiazole, benzoimidazole, benzothiophene, methylenedioxyphenyl, quinoline, isoquinoline, napthridine, indole, benzofuran, purine, benzofuran, deazapurine, or indolizine.
  • aryl groups having heteroatoms in the ring structure may also be referred to as "aryl heterocycles,” “heterocycles,” “heteroaryls,” or “heteroaromatics.”
  • the aromatic ring can be substituted at one or more ring positions with such substituents as described above, as for example, halogen, hydroxyl, alkoxy, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkylaminocarbonyl, aralkylaminocarbonyl, alkenylaminocarbonyl, alkylcarbonyl, arylcarbonyl, aralkylcarbonyl, alkenylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl.
  • phosphate phosphonato, phosphinato, cyano
  • amino including, for example, alkylamino, dialkylamino, arylamino, diarylamino, and alkylarylamino
  • acylamino including, for example, alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido
  • amidino imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, alkylsulf ⁇ nyl, sulfonato, sulfamoyl, sulfonamido, nitro, trifluoromethyl, cyano, azido, heterocyclyl, alkylaryl, or an aromatic or heteroaromatic moiety.
  • Aryl groups can also be fused or bridged with alicyclic or heterocyclic rings, which are not aromatic so as to form a multicyclic system (e.g., tetralin, and methylenedioxyphenyl) .
  • heterocyclyl or “heterocyclic group” include closed ring structures, e.g., 3- to 10-, or 4- to 7-membered rings, which include one or more heteroatoms.
  • Heterocyclyl groups can be saturated or unsaturated and include pyrrolidine, oxolane, thiolane, piperidine, piperazine, morpholine, lactones, lactams such as azetidinones and pyrrolidinones, sultams, sultones, and the like.
  • the heterocyclic ring can be substituted at one or more positions with such substituents as described above, as for example, halogen, hydroxyl, alkylcarbonyloxy, arylcarbonyloxy, alkoxycarbonyloxy, aryloxycarbonyloxy, carboxylate, alkylcarbonyl, alkoxycarbonyl, aminocarbonyl, alkylthiocarbonyl, alkoxyl, phosphate, phosphonato, phosphinato, cyano, amino (including alkyl amino, dialkylamino, arylamino, diarylamino, and alkylarylamino), acylamino (including alkylcarbonylamino, arylcarbonylamino, carbamoyl and ureido), amidino, imino, sulfhydryl, alkylthio, arylthio, thiocarboxylate, sulfates, sulfonate, sulfamoy
  • ether includes compounds or moieties, which contain oxygen bonded to two different carbon atoms or heteroatoms.
  • alkoxyalkyl which refers to an alkyl, alkenyl, or alkynyl group covalently bonded to an oxygen atom which is covalently bonded to another alkyl group.
  • esters includes compounds and moieties, which contain a carbon or a heteroatom bound to an oxygen atom, which is bonded to the carbon of a carbonyl group.
  • ester includes alkoxycarboxy groups such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, butoxycarbonyl, pentoxycarbonyl, etc.
  • alkyl, alkenyl, or alkynyl groups are as defined above.
  • hydroxy or "hydroxyl” includes groups with an -OH or -O " .
  • Carboxyl or “carboxy” includes groups with an -CO 2 H or -CO 2 " .
  • halogen includes fluorine, bromine, chlorine, iodine, etc.
  • perhalogenated generally refers to a moiety wherein all hydrogens are replaced by halogen atoms.
  • Heteroatom includes atoms of any element other than carbon or hydrogen. Examples of heteroatoms include nitrogen, oxygen, sulfur and phosphorus.
  • the structure of some of the compounds of the invention includes asymmetric carbon atoms. It is to be understood accordingly that the isomers arising from such asymmetry (e.g., all enantiomers and diastereomers) are included within the scope of the invention, unless indicated otherwise. Such isomers are obtained in substantially pure form by classical separation techniques and by stereochemically controlled synthesis. Furthermore, the structures and other compounds and moieties discussed in this application also include all tautomers thereof. Alkenes and amines can include either the E- or Z-geometry, where appropriate.
  • Combination therapy includes the administration of a modulator compound of the invention and at least a second agent as part of a specific treatment regimen intended to provide the beneficial effect from the co-action of these therapeutic agents.
  • the beneficial effect of the combination includes, but is not limited to, pharmacokinetic or pharmacodynamic co-action resulting from the combination of therapeutic agents.
  • Administration of these therapeutic agents in combination typically is carried out over a defined time period (usually minutes, hours, days or weeks depending upon the combination selected).
  • “Combination therapy” may, but generally is not, intended to encompass the administration of two or more of these therapeutic agents as part of separate monotherapy regimens that incidentally and arbitrarily result in the combinations of the present invention.
  • Combination therapy is intended to embrace administration of these therapeutic agents in a sequential manner, that is, wherein each therapeutic agent is administered at a different time, as well as administration of these therapeutic agents, or at least two of the therapeutic agents, in a substantially simultaneous manner.
  • Substantially simultaneous administration can be accomplished, for example, by administering to the subject a single capsule having a fixed ratio of each therapeutic agent or in multiple, single capsules for each of the therapeutic agents.
  • Sequential or substantially simultaneous administration of each therapeutic agent can be effected by any appropriate route including, but not limited to, inhalation, oral routes, intravenous routes, intramuscular routes, subcutaneous, rectal, intraperitoneal, parenteral, transdermal, gastrointestinal, and direct absorption through mucous membrane tissues.
  • the therapeutic agents can be administered by the same route or by different routes.
  • a first therapeutic agent of the combination selected may be administered by intravenous injection while the other therapeutic agents of the combination may be administered orally.
  • therapeutic agents may be administered orally or by intravenous injection.
  • the sequence in which the therapeutic agents are administered is not narrowly critical.
  • “Combination therapy” also can embrace the administration of the therapeutic agents as described above in further combination with other biologically active ingredients and non-drug therapies (e.g., surgery or radiation treatment).
  • the combination therapy further comprises a non-drug treatment
  • the non- drug treatment may be conducted at any suitable time so long as a beneficial effect from the co- action of the combination of the therapeutic agents and non-drug treatment is achieved.
  • the beneficial effect is still achieved when the non-drug treatment is temporally removed from the administration of the therapeutic agents, perhaps by days or even weeks.
  • the exemplary compounds provided here can be used in the treatment of cellular proliferation disorders, such as cancer.
  • Treatment of cellular proliferation disorders is intended to include inhibition of proliferation including rapid proliferation.
  • cellular proliferation disorder includes disorders characterized by undesirable or inappropriate proliferation of one or more subset(s) of cells in a multicellular organism.
  • cancer refers to various types of malignant neoplasms, most of which can invade surrounding tissues, and may metastasize to different sites (see, for example, PDR Medical Dictionary 1st edition (1995)).
  • neoplasm and "tumor” refer to an abnormal tissue that grows by cellular proliferation more rapidly than normal and continues to grow after the stimuli that initiated proliferation is removed (see, for example, PDR Medical Dictionary 1st edition (1995)). Such abnormal tissue shows partial or complete lack of structural organization and functional coordination with the normal tissue which may be either benign (i.e., benign tumor) or malignant (i.e., malignant tumor). Treating a disorder characterized by abnormal cellular proliferation is intended to include the prevention of the growth of neoplasms in a subject or a reduction in the growth of pre-existing neoplasms in a subject. Such inhibition also includes the inhibition of the metastasis of a neoplasm from one site to another.
  • neoplasms are preferably sensitive to the exemplary compounds disclosed here and/or interferon.
  • types of neoplasms include but are not limited to those neoplasms associated with cancers of the breast, skin, bone, prostate, ovaries, uterus, cervix, liver, lung, brain, larynx, gallbladder, pancreas, rectum, parathyroid, thyroid, adrenal gland, immune system, neural tissue, head and neck, colon, stomach, bronchi, kidneys.
  • certain exemplary compounds provided here can be used in the treatment of viral infections.
  • Treatment of viral infections is intended to include the use of the compounds disclosed here to prevent, or substantially inhibit, the initiation of viral protein synthesis.
  • Treatment of viral infections is also intended to include the use combination of an interferon and the novel compounds disclosed here to inhibit initiation of viral protein synthesis, inhibit elongation of viral protein synthesis, inhibit primary viral RNA transcription, reduce viral infectivity, and reduce budding and release of virions.
  • the term "viral infection,” as used herein, refers to one or more cells, which have been, infected with a virus, preferably a DNA or RNA virus.
  • RNA viruses include, but are not limited to, virus families such as picornaviridae (e.g., polioviruses), reoviridae (e.g., rotaviruses), togaviridae (e.g., encephalitis viruses, yellow fever virus, rubella virus), orthomyxoviridae (e.g., influenza viruses), paramyxoviridae (e.g., respiratory syncytial virus, measles virus, mumps virus, parainfluenza virus), rhabdoviridae (e.g., rabies virus), coronaviridae, bunyaviridae, flaviviridae, filoviridae, arenaviridae, bunyaviridae, and retroviridae (e.g., human T-cell lymphotropic viruses (HTLV), human immunodeficiency viruses (HIV)).
  • picornaviridae e.g., polioviruses
  • DNA viruses include, but are not limited to, virus families such as papovaviridae (e.g., papilloma viruses), adenoviridae (e.g., adenovirus), herpesviridae (e.g., herpes simplex viruses), and poxviridae (e.g., variola viruses).
  • virus families such as papovaviridae (e.g., papilloma viruses), adenoviridae (e.g., adenovirus), herpesviridae (e.g., herpes simplex viruses), and poxviridae (e.g., variola viruses).
  • the viral infection is caused by hepatitis B virus, hepatitis C virus, and/or HIV.
  • Other suitable RNA and DNA viruses will be readily selected by the person of ordinary skill in the art, given the benefit of this disclosure.
  • the compounds disclosed here can be used in the treatment of non-proliferative, degenerative disorders associated with aberrant translation initiation.
  • Treatment of non-proliferative, degenerative diseases is intended to include the use of small molecules to inhibit translation initiation.
  • non-proliferative degenerative disorder is intended to include diseases characterized by a loss of function of cells, tissues, and/or organs due to aberrant translation initiation.
  • Non-proliferative degenerative disorders include, but are not limited to, disorders such as Alzheimer's disease and insulin resistance.
  • Other non-proliferative degenerative disorders will be recognized by the person of ordinary skill in the art, given the benefit of this disclosure.
  • anionic group refers to a group that is negatively charged at physiological pH.
  • Preferred anionic groups include carboxylate, sulfate, sulfonate, sulfinate, sulfamate, tetrazolyl, phosphate, phosphonate, phosphinate, or phosphorothioate or functional equivalents thereof.
  • "Functional equivalents" of anionic groups are intended to include bioisosteres, e.g., bioisosteres of a carboxylate group. Bioisosteres encompass both classical bioisosteric equivalents and non-classical bioisosteric equivalents.
  • a particularly preferred anionic group is a carboxylate.
  • the compounds of the invention and the other pharmacologically active agent may be administered to a patient simultaneously, sequentially, or in combination. It will be appreciated that when using a combination of the invention, the compound of the invention and the other pharmacologically active agent may be in the same pharmaceutically acceptable carrier and therefore administered simultaneously. They may be in separate pharmaceutical carriers such as conventional oral dosage forms, which are taken simultaneously.
  • the term “combination” further refers to the case where the compounds are provided in separate dosage forms and are administered sequentially.
  • R 1 is selected from hydrogen, C 1 -C 6 alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
  • R 2 is selected from methyl, phenyl, substituted phenyl, benzyl, and substituted benzyl; or together R 1 and R 2 form a phenyl ring; at least one of R 3 and R 4 is selected from hydrogen, COOH, COOR a , CH 2 OH, and CONH 2 , and the other of R 3 and R 4 is selected from C 1 -C 6 alkyl, phenyl, substituted phenyl, benzyl and substituted benzyl, and further where:
  • R a is C 1 -C 6 alkyl, substituted benzyl and substituted phenyl are benzyl and phenyl moieties, respectively, wherein at least one hydrogen has been replaced with substituent selected from F, Cl, Br, I, NO 2 , CN,
  • R 1 is hydrogen
  • R 2 is phenyl or substituted phenyl
  • one of R 3 or R 4 is COOH
  • one of R 3 or R 4 is CH 2 OH
  • R 4 is benzyl.
  • COOH is reacted to produce COOCH 3 , or CH 2 OH.
  • V involves: reacting thiosemicarbazide with an ⁇ -bromoketone of Formula II:
  • R 1 is selected from hydrogen, C 1 -C 6 alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
  • R 2 is selected from phenyl, substituted phenyl, benzyl, and substituted benzyl; or together Ri and R 2 form a phenyl ring;
  • R 3 is selected from C 1 -C 6 alkyl, phenyl, substituted phenyl, benzyl and substituted benzyl, further wherein: substituted benzyl and substituted phenyl are benzyl and phenyl moieties, respectively, where at least one hydrogen has been replaced with any one of the substituent selected from F, Cl, Br, I, NO 2 , CN, COR 3 , COOR a , COOH, and C(O)H, where R a is C 1 -C 6 alkyl.
  • R 3 is benzyl or R 2 is phenyl.
  • n 0 or 1
  • X is S or C, such that when n is 0, X is S;
  • R b and R 0 are independently selected from H, Ci -C 6 alkyl, F, Cl, Br, I, NO 2 , CN, COR a , COOR a , COOH, and C(O)H, where R 3 is C 1 -C 6 alkyl.
  • n 0 and X is S or n is 1 and X is C.
  • R b and R 0 are each H.
  • R 1 is selected from Cj-C 6 alkyl, phenyl, substituted phenyl, benzyl, and substituted benzyl;
  • R 2 is selected from OH, and OR a , wherein R 3 is Cj-C 6 alkyl;
  • R 3 is selected from phenyl, substituted phenyl, benzyl, substituted benzyl, and Cj-C 6 alkyl, further where: substituted benzyl and substituted phenyl are benzyl and phenyl moieties, respectively, wherein at least one hydrogen has been replaced with substituent selected from F, Cl 3 Br, I, NO 2 , CN, COR 3 , COOR a , COOH, and C(O)H,
  • R 2 is OH or OR 3 .
  • R 3 is methyl or R 3 is benzyl.
  • Rj may be ethyl.
  • R b and R 0 are independently selected from H, C 1 -C 6 alkyl, F, Cl, Br, I, NO 2 , CN, COR 3 , COOR 3 , COOH, and C(O)H, where R 3 is C 1 -C 6 alkyl.
  • R b and R 0 are each H.
  • R b and R 0 are independently selected from H, Ci-C 6 alkyl, F, Cl, Br, I, NO 2 , CN, COR 3 , COOR 3 , COOH, and C(O)H, where Ra is C 1 -C 6 alkyl.
  • R b and R 0 are each H.
  • R b and R 0 are independently selected from H, Ci-C 6 alkyl, F, Cl, Br, I, NO 2 , CN, COR a , COOR a , COOH, and C(O)H, where R 3 is C 1 -C 6 alkyl.
  • R b and R 0 are each H.
  • R b and R 0 are independently selected from H, C 1 -C 6 alkyl, F, Cl, Br, I, NO 2 , CN, COR a , COOR 3 , COOH, and C(O)H, where R 3 is C 1 -C 6 alkyl.
  • R b and R 0 are each H.
  • FIGURE IA is a graph showing titration of a fluorescein-labeled eIF4G peptide with eIF4E causes increased fluorescence anisotropy indicating binding of the peptide.
  • the data is fit to a two state binding model.
  • FIGURE IB is a graph showing competitive inhibition of labeled peptide binding to eIF4E by an unlabeled eIF4GII peptide as measured by decrease in fluorescence polarization. The data is fit to a three state competitive binding model.
  • FIGURE 1C shows the chemical structure of EGI-I.
  • FIGURE ID is a graph showing competitive inhibition of labelled peptide binding to eIF4E by the compound EGI-I as measured by decrease in fluorescence polarization. The data is fit to a three state competitive binding model.
  • FIGURE IE is a schematic showing chemical shift perturbations of eIF4E induced by eIF4G peptide binding.
  • the surface representation structure of the crystal structure murine eIF4E (light areas) in complex with the eIF4GII consensus peptide (circled) is shown: eIF4E residues which shift in HSQC peak position on titration with an eIF4GII peptide are shaded.
  • FIGURE IF is a schematic showing that EGI-I interacts with the eIF4G recognition surface of eIF4E.
  • the same structure as FIGURE IE is shown, with eIF4E residues in the eIF4G peptide binding region strongly affected by EGI-I (shift in peak position or greater than 35% signal attenuation) labelled and shaded.
  • FIGURE 2A is a diagram showing the dual luciferase mRNA reporter construct containing Renilla luciferase (translated in cap-dependent fashion) and firefly luciferase (translation driven by cricket paralysis virus IRES).
  • FIGURE 2B is a graph showing that EGI-I inhibits cap-dependent translation in rabbit reticulocyte lysate as measured by synthesis of Renilla luciferase. Error bars correspond to standard error of the mean.
  • FIGURE 2C is a graph showing that EGI-I does not inhibit IRES driven translation in rabbit reticulocyte lysate as measured by synthesis of firefly luciferase. Error bars correspond to standard error of the mean.
  • FIGURE 2D is a photograph of a series of immunoblots showing the effect of EGI-I on association of eIF4E with eIF4G and 4E-BP1 in rabbit reticulocyte lysate, as determined by a m 7 GTP Sepharose pull-down assay and Western blotting.
  • FIGURE 3 A is a photograph of a series of immunoblots showing the effect of 6 hrs EGI- 1 treatment on association of eIF4E with eIF4G and 4E-BP1 in Jurkat cells as determined by a m 7 GTP Sepharose pull-down assay and Western blotting.
  • EGI-I inhibits eIF4F complex formation and the expression of proteins encoded by mRNAs with highly structured 5' UTRs in cells.
  • FIGURE 3B is a photograph of a series of immunoblots showing the effect of EGI-I treatment over 8 hours on protein levels as measured by Western blotting of Jurkat cell extracts.
  • FIGURE 3C is a graph showing that EGI-I does not affect nucleocytoplasmic transport or stability of c-myc and Bcl-xL mRNA in Jurkat cells. Cells were treated with compound for 8 hrs and relative abundance of the two mRNAs relative to ⁇ -actin was determined by quantitative real-time PCR.
  • FIGURE 4A is a graph showing that EGI-I induces loss of cell viability in Jurkat cells as measured by decrease in intracellular ATP level. Bars correspond to standard error of the mean.
  • FIGURE 4B is a bar graph showing that EGI-I induces DNA fragmentation in Jurkat cells. Jurkat cells were treated with 60 ⁇ M EGI-I or 6.65 ⁇ M camptothecin for 24 hours with or without 100 ⁇ M zV AD-FMK. The percentage of cells having sub-Gl DNA content was determined via FACS analysis. Bars correspond to standard error of the mean.
  • FIGURE 4C is a series of photographs showing that EGI-I induces fragmented nuclear morphology in Jurkat cells.
  • Cells were treated with 60 ⁇ M EGI-I for 24 hours, stained with Hoechst 33342 dye, and visualized by fluorescence microscopy.
  • FIGURE 4D is a graph showing that EGI-I inhibits proliferation of A549 lung cancer cells as measured by the SRB assay after a five day growth period. Error bars correspond to standard error of the mean.
  • FIGURE 5A is a diagram of the structure of eIF4E bound to eIF4G.
  • FIGURE 5B is a dot plot showing loss of FP signal on titration with unlabeled eIF4G peptide.
  • FIGURE 5C is a diagram of the chemical structure of hit compounds, EGI-I (compound 154300) and 6006288.
  • FIGURE 5D is a dot plot showing inhibition of labeled peptide binding by hit compounds.
  • FIGURE 6A is a series of graphs showing data from a titration of 50 ⁇ M eIF4E with EGI-I (compoundl 54300) using multidimensional NMR.
  • FIGURE 6B is a series of graphs showing data from a titration of 50 ⁇ M eIF4E with compound 60062880 using multidimensional NMR.
  • FIGURE 6C is a diagram of a docked model of EGI-I (compound 154300) bound to eIF4E.
  • FIGURES 7A-C are a series of graphs showing the results of in vitro translation assays with in the presence of titrated concentrations ( ⁇ M) of compounds.
  • FIGURE 7A is a graph showing a titration with emetine
  • FIGURE 3B is a graph showing a titration with m7GDP
  • FIGURE 7C is a graph showing titration with EGI-I (154300).
  • FIGURE 8 A is a graph showing the results of a proliferation assay using A549 cells in the presence of various concentrations ( ⁇ M) of compound.
  • FIGURE 8B is a graph showing the results of a survival assay using A549 cells in the presence of various concentrations ( ⁇ M) of compound.
  • FIGURE 9 is a series of diagrams showing the chemical structure of inhibitory compounds identified from Bionet, Peakdale and Maybridge Libraries (compounds 37629, 21573, 35197, 21551, and 29578).
  • FIGURE 10 is a diagram showing eukaryotic translation initiation.
  • FIGURE 11 is a diagram showing cap-dependent recruitment of niRNA to the 43 S ribosomal subunit.
  • FIGURE 12 is a diagram showing that translation can also be initiated via an internal ribosome entry site (IRES) in a cap-independent way.
  • IRES internal ribosome entry site
  • FIGURE 13 is a diagram showing the structure of eIF4E.
  • FIGURE 14 is a diagram showing that eIF4G wraps around the N-terminus of eIF4E and triggers a mutual folding event.
  • FIGURE 15 is a diagram showing the eIF4E binding interface of eIF4G (393-490). eIF4G (393-490) does not form a globular structure.
  • FIGURE 16 is a diagram showing eukaryotic translation initiation.
  • FIGURE 17 is a diagram showing that cap-dependent initiation is down-regulated by 4E- binding proteins (4EBPs).
  • 4EBPs inhibit recruitment of 43S ribosome by blocking eIF4G- binding site.
  • 4EBPs shared the YxxxxL ⁇ consensus sequence with eIF4G.
  • FIGURES 18A and 18B are diagrams showing that hyperphosphorylation of eIF4E- bound 4EBP (mTOR and PI3K) leads to dissociation of 4EBP and initiation.
  • FIGURE 19 is a series of photographs showing nuclear staining with Hoechst 33342. The addition of a 4E/4G inhibitor causes apoptosis in Jurkat cells.
  • FIGURE 20 is a diagram showing the chemical structure of active compounds from NCI diversity library.
  • FIGURES 21A-21D are graphs showing 1H-15N HSQC mouse eIF4E
  • FIGURE 22 is a graph showing FP of labeled peptide decreases back to baseline level upon the addition of unlabelled eIF4G peptide. Potential inhibitors of eIF4G binding to eIF4E are identified based on loss of fluorescence polarization.
  • FIGURE 23 is a diagram showing the eIF4E/4E-BP homology model. Small chemicals block binding of endogenous 4EBPs to eIF4E.
  • FIGURE 24 is a graph showing design of fluorescence polarization assay. A peptide containing binding motif was synthesized with fluorescent label: KYTYDELFQLK(SEQ ID NO: 2)-Fluorescein. Addition of eIF4E to the peptide causes increased FP.
  • FIGURE 25 is a graph showing inhibition of peptide binding by ICCB compounds.
  • FIGURE 26 is a graph showing inhibition of in vitro translation by ICCB compounds.
  • FIGURE 27 is a diagram showing a reporter gene to be used in a bicistronic translation assay.
  • FIGURE 28 is a graph showing the results of a cell proliferation assay.
  • A549 cells which are human lung cancer cells, are grown in plates for five days in medium containing 5% FCS and compound. The number of cells is quantified by staining with sulforhodamine B.
  • FIGURE 29 A is a diagram showing the location of the binding sites of compound ICCB- 15644.
  • FIGURE 29B is a dot blot.
  • FIGURES 3 OA-B are diagrams showing inhibitor binding sites.
  • FIGURE 31 is a diagram showing inhibitor docked with TreeDock based on NMR perturbation data.
  • FIGURE 32 is a diagram showing Crystal structure of mouse eIF4E bound to a peptide derived from eIF4GII.
  • eIF4E is shown in surface representation (dark shading represent O and N atoms), The eIF4GII peptide is shown in ribbon.
  • Key Residues Y69, W73, Y76, L131, L135 and 1138 form a hydrophobic patch, (shown in light shading) which forms a putative "hot spot" for binding the eIF4E-binding domain in eIF4GII and 4E-BP.
  • FIGURE 33 A is a diagram showing Predicted binding mode generated by Treedock docking program. The illustration was made with the program InSight II. Displayed is a contact surface between mouse eIF4E protein (dark shading represent O and N atoms), and the hit compound 1. Amino acid residues V69, W73, Yl 6, L131, L135 and 1138 (light shading) are the eIF4E interaction surface with eIF4G peptide.
  • FIGURE 33B is a diagram showing Simulated Interaction of inhibitor with mouse eIF4E amino acid residue Trp73, His 78.
  • FIGURE 34 is a table showing the biological activities of 2-thiazolyl hydrazone analogues modified at position 4 with substituted phenyl moieties.
  • FIGURES 35A-B are graphs showing IC 5O was measured using fluorescent polarization (FP) assay. Results are presented as ratios of the compounds IC 50 values (IC 50 (comp.)) to the IC 50 value of the eIF4G-derived peptide (IC 50 (pept.)).
  • GI 50 was measured using Alamar Blue assay. The values indicate the average concentration needed to inhibit 50% of cell proliferation.
  • tumor cells are characterized by aberrant protein translation initiation mechanisms, e.g., association or binding of certain translation initiation factors.
  • aberrant protein translation initiation mechanisms e.g., association or binding of certain translation initiation factors.
  • the interaction of the cap-binding protein eIF4E with the mRNA cap, the scaffold protein eIF4G, and the regulatory 4E-BPs are involved in cell transformation.
  • Small-molecule inhibitors of the eIF4E/eIF4G interaction have been identified and found to possess anti-tumor activity.
  • eIF4A This process is facilitated by eIF4A, with the requirement for its helicase activity directly proportional to the amount of secondary structure in the 5' UTR that must be melted for scanning to occur.
  • All eIF4G proteins bind eIF4E through a motif of sequence Y(X) 4 L ⁇ , where X is variable and ⁇ is hydrophobic. This motif forms a helical peptide structure which binds a conserved surface of hydrophobic residues on the dorsal side of eIF4E.
  • Cellular mRNAs differ greatly in their requirement for eIF4F for efficient translation and in the composition of the 5' UTR.
  • the majority of growth and proliferation related proteins are encoded by "weak" mRNAs containing long highly structured 5' UTRs which have lower translational efficiency than "strong" mRNAs, which contain relatively short and unstructured 5' UTRs.
  • Translation of weak mRNAs is highly eIF4F dependent and is preferentially enhanced when the level of eIF4F complex is increased by eIF4E overexpression.
  • the amount of eIF4E available for complex formation is controlled by a class of small proteins termed 4E-BPs which contain the Y(X) 4 L ⁇ motif and bind to the same surface as eIF4G.
  • 4E-BPs undergo a set of hierarchical phosphorylation events. Hyperphosphorylated forms of 4E-BPs bind eIF4E much more weakly than hypophosphorylated forms, and thus 4E-BP phosphorylation acts as a switch to up-regulate the level of eIF4F and cap-dependent translation. Misregulation of cap-dependent translation due to overexpression of eIF4E and the other components of the eIF4F complex is thought to play an important role in the development of many forms of cancer. In cultured mammalian cells overexpression of eIF4E or eIF4G induces malignant transformation while overexpression of 4E-BP1 partially reverses transformation by eIF4E. In addition, etopic expression of nonphosphorylatable forms of 4E- BPl can inhibit proliferation and/or induce apoptosis in cancer cell lines. Inhibition of the eIF4F complex is useful for cancer therapy.
  • inhibitors of this protein interaction were discovered using a fluorescence polarization screening assay.
  • Inhibitors described herein selectively suppress synthesis of growth factors and oncogene products. These molecules specifically bind to a conserved region of hydrophobic residues on the surface of eIF4E that is recognized by a conserved helical peptide motif in eIF4G, thus blocking the interaction of these two proteins.
  • traditional inhibitors of translation e.g., cyclohexamide
  • these molecules are selective inhibitors of cap-dependent translation, a significant improvement over existing general inhibitors of protein synthesis.
  • the compounds described herein were identified by screening the ChemBridge library (16,000 compounds), which block the binding of a fluorescently labeled eIF4G-derived peptide to eIF4E in a fluorescence polarization assay.
  • Three of the candidate inhibitors have estimated K D values of 10 ⁇ M or more: ICCB-5582 (10 ⁇ M), EGI-I or ICCB-15644 (2 ⁇ M), and ICCB- 6737 (1 ⁇ M).
  • NMR titration experiments demonstrate competitive binding of EGI-I to a surface region of eIF4E which interacts with a conserved peptide motif in eIF4G.
  • This compound displaces full-length eIF4G from eIF4E, causes increased binding of 4E-BP1 to eIF4E, and specifically inhibits cap-dependent translation.
  • EGI-I appears to specifically inhibit production of malignancy-related proteins with mRNAs containing highly structured 5' UTRs. All three of these compounds inhibited cap-dependent translation in vitro in the rabbit reticulocyte lysate system.
  • Compounds ICCB-5582 and ICCB-15644 inhibited the proliferation of cultured A549 cells (a lung cancer cell line), both with approximate IC50 values of 6 ⁇ M.
  • EGI-I induces apoptosis in the human Jurkat lymphoma cell line, and also inhibits the growth of the A549 lung cancer and HT29 colon cancer cell lines.
  • the identification of EGI-I provides a novel tool for the study of translationally regulated cellular processes and a potential starting point for the development of more potent inhibitors.
  • EGI-I competitively inhibits binding of eIF4G to eIF4E NMR spectroscopy was employed to characterize the interaction of EGI-I with eIF4E
  • Murine eIF4E is identical to the human protein in its structured portion, except for a D174E replacement at a structurally and functionally unimportant position. As murine eIF4E is unstable at the concentration levels required for triple resonance NMR experiments, a more soluble form of the protein was developed by fusing a solubility enhancement tag (SET), the 56 residue GBl domain of protin G, to the amino terminus of eIF4E.
  • SET solubility enhancement tag
  • the fusion protein exhibited significantly enhanced solubility and analysis of the HSQC spectra of native and tagged proteins confirmed that the tag had no affect on the structure of eIF4E.
  • the protein was titrated with EGI-I or the conserved peptide from eIF4GII and resulting changes in the 15 N HSQC spectrum were analyzed. Titration of GBl- eIF4E with EGI-I had no effect on the GBl resonances but caused selective line broadening of a subset of eIF4E peaks in the HSQC spectrum.
  • EGF-I inhibits eIF4F complex formation and cap-dependent translation
  • EGF-I inhibits eIF4F complex formation and the expression of proteins encoded by mRNAs with highly structured 5' UTRs in cells
  • EGI-I disrupts the eIF4F complex in human Jurkat T cells: after a 6 hour treatment with the compound eIF4G is displaced from eIF4E while binding of 4E- BPl is increased, similar to the effect in vitro (FIGURE 3A).
  • the total level of eIF4G or 4E- BPl is not significantly affected by the compound treatment.
  • EGI-I likely inhibits the production of proteins encoded by weak mRNAs with highly structured 5' UTRs in a preferential manner (e.g, Bcl-xL and c-myc) while having little or no effect on strong mRNAs such as ⁇ - actin.
  • EGI-I exhibits activity against cancer cell lines Further characterization of EGI-I in Jurkat cells showed that this compound has pro- apoptotic activity. After 24 hours, cells treated with the compound exhibit dose-dependent loss of cell viability as measured by cellular ATP level (FIGURE 4A). Flow cytometry analysis of cellular DNA content shows that EGI-I causes a large increase in the sub-Gl fraction (corresponding to fragmented DNA) (FIGURE 4B), which can be suppressed by co-treatment with the broad spectrum caspase inhibitor zV AD-FMK. Furthermore, the treated cells exhibit a fragmented nuclear morphology that is characteristic of apoptosis (FIGURE 4C). EGI-I also exhibits activity against other cancer cell lines.
  • the compound inhibits the growth of A549 lung cancer cells as measured by an SRB assay, with an ICs 0 of approximately 6 ⁇ M (FIGURE 4D).
  • EGI-I inhibits the growth of HT29 colon cancer cells with an ICsoof 9 ⁇ M. Such results can result from pro-apoptotic and/or antiproliferative activity in these cell lines.
  • EGI-I is a competitive inhibitor of binding of the conserved eIF4G recognition peptide to eIF4E and disrupts this protein complex both in vitro and in cells.
  • EGI-I is an inhibitor of cap-dependent translation and selectively downregulates the expression of proteins encoded by mRNAs with highly structured 5' UTRs, many of which have key roles in malignancy. The compound can induce apoptosis in Jurkat lymphoma cells and exhibits activity against other human cancer cell lines.
  • the identification of EGI-I provides a new tool for targeting the eIF4F complex which can be used in the study of numerous biological processes which depend on translational control. It also provides a starting point for development of more potent inhibitors.
  • Z/E isomer was further separated by HPLC-MS, using a 30 min linear gradient of 50- 75% of 0.05% HOAc in acetonitril 50% in 0.05% HOAc in water.
  • the gradient eluting solvents included 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • E isomer was further separated by HPLC-MS using a 30 min linear gradient of 50-75% of 0.05% HOAc in acetonitril 50% in 0.05% HOAc in water.
  • the gradient eluting solvents included.
  • Gradient eluting solvents included 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • E isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • E isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • 2-Phenyl-5-hydrazineo-l 5 3,4-thiadiazole (2k) were obtained by diazotization of 2-amino- 5-phenyl-l 5 3,4-thiadiazoles in hydrochloric acid with copper catalysis followed by treatment with hydrazine hydrate.
  • the final product (4k) was synthesized by condensation with ⁇ -keto acid.
  • 3-Phenyl-2-[(6-phenyl-pyridazin-3-yl)-hydrazono]-propionic acid (41) was synthesized by a similar fashion.
  • E is the predominant isomer. Variation in isomeric rations might be due to the different sizes of R 3 and R 4 group. This result is consistent with the report by Dimmock and Rezessy. However, they also both reported that the pure E isomers underwent E to Z isomerization after standing in solutions. In order to check the stability of the pure isomers to determine if there is transformation into Z/E mixtures in physiological condition, solution were prepared in deuterated eIF4E buffer and spectra were recorded by high resolution 1 H NMR after dissolution of pure isolated isomers as well as Ih, lday. Interestingly, the testing revealed that they are stable configurationally.
  • ZJE isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • ZJE isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitrile 50% : 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • Subjects diagnosed as having or at risk of developing a condition (e.g., tumor) in which eIF4E, F, or G are elevated are treated using the compounds described herein.
  • exemplary conditions include, e.g., tumors of the lung, breast, head (neurological tissues such as brain and spinal cord), neck, bladder, colon, prostate, liver, gastrointestinal tract, lung, lymphomas, and neuroblastomas.
  • Treatment with these compounds may also be beneficial for other cancers that overexpress other translation initiation or for non-cancerous proliferative disorders such as vein craft rejection and restinosis, as well as for non-proliferative degenerative disorders, disorders associated with aberrant apoptosis, and disorders associated with viral and bacterial infections in human and other mammals.
  • a therapeutic regimen is carried out by identifying a mammal, e.g., a human patient suffering from (or at risk of developing) a cancer or metastases or other proliferative disorders, non-proliferative degenerative disorders and disorders associated with viral and bacterial infections using standard methods. For example, inhibitory compounds are administered to an individual diagnosed with a cancer.
  • the compounds are preferably administered intravenously or orally.
  • EGI-I or compound 154300 is formulated into a salt to enhance its solubility and absorbance
  • compound 600628 is formulated with an emulsifier for oral administration or with a pharmaceutically-acceptable solvent for intravenous administration.
  • the compounds are formulated by combining the active compound(s) with pharmaceutically acceptable carriers, which are readily selected by those skilled in the art, given the benefit of this disclosure.
  • pharmaceutically acceptable carriers enable the exemplary compounds disclosed here to be formulated as tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • Pharmaceutical preparations for oral use are formulated with a solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents are added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • dragee cores are provided with suitable coatings.
  • concentrated sugar solutions can be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • pharmaceutical preparations for oral administration include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added. All formulations for oral administration should be in dosages suitable for such administration.
  • compositions may take the form of tablets or lozenges formulated in conventional manner.
  • the compounds can be conveniently delivered in the form of an aerosol spray presentation from pressurized packs or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • a suitable propellant e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas.
  • the dosage unit may be determined by providing a valve to deliver a metered amount.
  • Capsules and cartridges of gelatin for example, for use in an inhaler or insufflator can be formulated containing a powder mix of the compound and a suitable powder base such as lactose or starch.
  • the compounds may be formulated for parenteral administration by injection, e.g., by bolus injection or continuous infusion.
  • Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers, with an added preservative.
  • the compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilizing and/or dispersing agents.
  • pharmaceutical formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form.
  • suspensions of the active compounds can be prepared as appropriate oily injection suspensions.
  • suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.
  • Aqueous injection suspensions can contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran.
  • the suspension can also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • the active ingredient can be in powder form for constitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.
  • the compounds can also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • the compounds can also be formulated as a depot preparation.
  • Such long acting formulations can be administered by implantation or transcutaneous delivery (for example subcutaneously or intramuscularly), intramuscular injection or a transdermal patch.
  • the compounds can be formulated with suitable polymeric or hydrophobic materials (for example as an emulsion in an acceptable oil) or ion exchange resins, or as sparingly soluble derivatives, for example, as a sparingly soluble salt.
  • the pharmaceutical compositions also can include suitable solid or gel phase carriers or excipients. Examples of such carriers or excipients include but are not limited to calcium carbonate, calcium phosphate, various sugars, starches, cellulose derivatives, gelatin, and polymers such as polyethylene glycols.
  • compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion.
  • suitable carriers include physiological saline, bacteriostatic water, Cremophor ELTM (BASF, Parsippany, N. J.), or phosphate buffered saline (PBS).
  • the composition preferably is sterile and is fluid to the extent that it may be drawn into and/or delivered using a syringe.
  • compositions preferably are stable under the conditions of manufacture and storage and are be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition.
  • Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.
  • the compounds are prepared as oral compositions.
  • Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets.
  • the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules.
  • Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed.
  • Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
  • the tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
  • a binder such as microcrystalline cellulose, gum tragacanth or gelatin
  • an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, or corn starch
  • a lubricant such as magnesium stearate or Sterotes
  • a glidant such as colloidal silicon dioxide
  • the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems.
  • a controlled release formulation including implants and microencapsulated delivery systems.
  • Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art.
  • the materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc.
  • Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These materials may be prepared according to methods known to those skilled in the art, for example, as described in U.S. Pat. No. 4,522,811.
  • An appropriate dosage level is generally be about 0.001 to 50 mg/kg patient body weight per day, which may be administered in single or multiple doses. If given orally, the dosage level may be about 0.01 to about 30 mg/kg per day, e.g., 0.01 to about 1, 3, 5, 7, 10, 15, 20, 25 or 30 mg/kg per day. If given intravenously, the dosage levels may be somewhat lower, e.g., 0.01 to about 0.3, 1, 3, 5, 7 or 10 mg/kg per day. For example, in the treatment or prevention of a disorder of the central nervous system, a suitable oral dosage level may be about 0.01 to about 30 mg/kg per day, e.g., 0.01 to about 1, 3, 5, 7, 10, 15, 20, 25 or 30 mg/kg per day.
  • the compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day. It will be appreciated that the amount of the compound of the invention required for use in any treatment will vary not only with the particular compounds or composition selected but also with the route of administration, the nature of the condition being treated, and the age and condition of the patient, and will ultimately be at the discretion of the attendant physician.
  • the compositions and combination therapies of the invention may be administered in combination with a variety of pharmaceutical excipients, including stabilizing agents, carriers and/or encapsulation formulations as described herein.
  • compositions of the present invention comprise an effective amount of the compounds of the invention, dissolved or dispersed in a pharmaceutically acceptable carrier or aqueous medium.
  • “Pharmaceutically or pharmacologically acceptable” include molecular entities and compositions that do not produce an adverse, allergic or other untoward reaction when administered to an animal, or a human, as appropriate.
  • “Pharmaceutically acceptable carrier” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • preparations meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologies standards.
  • compositions and combination therapies of the invention are generally formulated for parenteral administration, e.g., formulated for injection via the intravenous, intramuscular, subcutaneous, intralesional, or even intraperitoneal routes.
  • parenteral administration e.g., formulated for injection via the intravenous, intramuscular, subcutaneous, intralesional, or even intraperitoneal routes.
  • the preparation of an aqueous composition that contains a composition of the invention or an active component or ingredient will be known to those of skill in the art in light of the present disclosure.
  • such compositions are prepared as injectables, either as liquid solutions or suspensions; solid forms suitable for using to prepare solutions or suspensions upon the addition of a liquid prior to injection can also be prepared; and the preparations can also be emulsified.
  • Other formulations include an ointment, paste, spray, patch, cream, gel, resorbable sponge, or foam. Such formulations are produced using methods well known in the art.
  • the compound is administered topically.
  • the compound is administered to the bladder using methods well known in the art, e.g., using a catheter to inflate the bladder with a solution containing the compound.
  • a cream or ointment is applied to the area of skin affected by the tumor.
  • Tumor cells in the liver are treated by infusing into the liver vasculature a solution containing the compound.
  • the compounds are administered by implanting (either directly into an organ such as the liver or subcutaneously) a solid or resorbable matrix which slowly releases the compound into adjacent and surrounding tissues of the subject.
  • the compound is systemically administered or locally administered directly into CNS tissue.
  • the compound is administered intravenously or intrathecally (i.e., by direct infusion into the cerebrospinal fluid).
  • a compound-impregnated wafer or resorbable sponge is placed in direct contact with CNS tissue.
  • the compound is infused into the brain or cerebrospinal fluid using known methods.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions; formulations including sesame oil, peanut oil or aqueous propylene glycol; and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form is sterile and fluid to the extent that easy syringability exists. It remains stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi.
  • Solutions of active compounds as free base or pharmacologically acceptable salts are prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • Therapeutic or pharmacological compositions of the present invention will generally comprise an effective amount of the component(s) of the combination therapy, dissolved or dispersed in a pharmaceutically acceptable medium.
  • Pharmaceutically acceptable media or carriers include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Supplementary active ingredients can also be incorporated into the therapeutic compositions of the present invention. The preparation of pharmaceutical or pharmacological compositions will be known to those of skill in the art in light of the present disclosure.
  • compositions may be prepared as mjectables, either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection; as tablets or other solids for oral administration; as time release capsules; or in any other form currently used, including cremes, lotions, mouthwashes, inhalants and the like.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum-drying and freeze-drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • DMSO dimethyl methacrylate
  • saline-based washes a formulation of saline-based washes
  • therapeutic formulations in accordance with the present invention may also be reconstituted in the form of mouthwashes, or in conjunction with antifungal reagents. Inhalant forms are also envisioned.
  • the therapeutic formulations of the invention may also be prepared in forms suitable for topical administration, such as in cremes and lotions.
  • Suitable preservatives for use in such a solution include benzalkonium chloride, benzethonium chloride, chlorobutanol, thimerosal and the like.
  • Suitable buffers include boric acid, sodium and potassium bicarbonate, sodium and potassium borates, sodium and potassium carbonate, sodium acetate, sodium biphosphate and the like, in amounts sufficient to maintain the pH at between about pH 6 and pH 8, and preferably, between about pH 7 and pH 7.5.
  • Suitable tonicity agents are dextran 40, dextran 70, dextrose, glycerin, potassium chloride, propylene glycol, sodium chloride, and the like, such that the sodium chloride equivalent of the ophthalmic solution is in the range 0.9 plus or minus 0.2%.
  • Suitable antioxidants and stabilizers include sodium bisulfite, sodium metabisulfite, sodium thiosulfite, thiourea and the like.
  • Suitable wetting and clarifying agents include polysorbate 80, polysorbate 20, poloxamer 282 and tyloxapol.
  • Suitable viscosity-increasing agents include dextran 40, dextran 70, gelatin, glycerin, hydroxyethylcellulose, hydroxmethylpropylcellulose, lanolin, methylcellulose, petrolatum, polyethylene glycol, polyvinyl alcohol, polyvinylpyrrolidone, carboxymethylcellulose and the like.
  • therapeutics are administered in a manner compatible with the dosage formulation, and in such amount as is pharmacologically effective.
  • the formulations are easily administered in a variety of dosage forms, such as the type of injectable solutions described above, but drug release capsules and the like can also be employed.
  • the quantity of active ingredient and volume of composition to be administered depends on the host animal to be treated. Precise amounts of active compound required for administration depend on the judgment of the practitioner and are peculiar to each individual.
  • a minimal volume of a composition required to disperse the active compounds is typically utilized. Suitable regimes for administration are also variable, but would be typified by initially administering the compound and monitoring the results and then giving further controlled doses at further intervals.
  • a suitably buffered, and if necessary, isotonic aqueous solution would be prepared and used for intravenous, intramuscular, subcutaneous or even intraperitoneal administration.
  • An exemplary dosage is dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermolysis fluid or injected at the proposed site of infusion, (see for example, Remington's Pharmaceutical Sciences 15th Edition, pages 1035-1038 and 1570-1580).
  • active compounds are administered orally. This is contemplated for agents which are generally resistant, or have been rendered resistant, to proteolysis by digestive enzymes. Such compounds are contemplated to include chemically designed or modified agents; dextrorotatory peptides; and peptide and liposomal formulations in time release capsules to avoid peptidase and lipase degradation.
  • Pharmaceutically acceptable salts include acid addition salts and which are formed with inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like. Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • inorganic acids such as, for example, hydrochloric or phosphoric acids, or such organic acids as acetic, oxalic, tartaric, mandelic, and the like.
  • Salts formed with the free carboxyl groups can also be derived from inorganic bases such as, for example, sodium, potassium, ammonium, calcium, or ferric hydroxides, and such organic bases as isopropylamine, trimethylamine, histidine, procaine and the like.
  • the carrier is optionally a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like.
  • isotonic agents for example, sugars or sodium chloride.
  • Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compounds in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredients into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • sterile powders for the preparation of sterile injectable solutions the preferred methods of preparation are vacuum-drying and freeze drying techniques which yield a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.
  • the preparation of more, or highly, concentrated solutions for direct injection is also contemplated, where the use of DMSO as solvent is envisioned to result in extremely rapid penetration, delivering high concentrations of the active agents to a small area.
  • suppositories include suppositories.
  • traditional binders and carriers may include, for example, polyalkylene glycols or triglycerides; such suppositories may be formed from mixtures containing the active ingredient in the range of 0.5% to 10%, preferably l%-2%.
  • Oral formulations include such normally employed excipients as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, cellulose, magnesium carbonate and the like. These compositions take the form of solutions, suspensions, tablets, pills, capsules, sustained release formulations or powders.
  • oral pharmaceutical compositions will comprise an inert diluent or assimilable edible carrier, or they may be enclosed in hard or soft shell gelatin capsule, or they may be compressed into tablets, or they may be incorporated directly with the food of the diet.
  • the active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tables, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 75% of the weight of the unit, or preferably between 25-60%.
  • the amount of active compounds in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder, as gum tragacanth, acacia, cornstarch, or gelatin; excipients, such as dicalcium phosphate; a disintegrating agent, such as corn starch, potato starch, alginic acid and the like; a lubricant, such as magnesium stearate; and a sweetening agent, such as sucrose, lactose or saccharin may be added or a flavoring agent, such as peppermint, oil of wintergreen, or cherry flavoring.
  • a binder as gum tragacanth, acacia, cornstarch, or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a flavor
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup of elixir may contain the active compounds sucrose as a sweetening agent methyl and propylparabensas preservatives, a dye and flavoring, such as cherry or orange flavor.
  • Suitable dispersing or suspending agents for aqueous suspensions include synthetic and natural gums such as tragacanth, acacia, alginate, dextran, sodium carboxymethylcellulose, methylcellulose, polyvinylpyrrolidone or gelatin.
  • compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders.
  • the liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as set out above.
  • the compositions are administered by the oral or nasal respiratory route for local or systemic effect.
  • Compositions in preferably sterile pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face mask, tent or intermittent positive pressure breathing machine.
  • Solution, suspension or powder compositions may be administered, preferably orally or nasally, from devices which deliver the formulation in an appropriate manner.
  • the compound of this invention is administered orally, topically, parenterally, by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • the majority of growth and proliferation proteins are encoded by "weak" mRNAs containing long highly structured 5' UTRs: in quiescent cells these are translated with much lower efficiency than "strong" mRNAs, which contain relatively short and unstructured 5' UTRs. Translation of these weak mRNAs has a much greater dependence on eIF4F and is preferentially enhanced when the level of eIF4F complexes is increased by eIF4E overexpression. The level of available eIF4E in the cell is regulated by a class of small proteins termed 4E-BPs. All eIF4G proteins contain a conserved motif of sequence Y(X) 4 L ⁇ , where X is variable and ⁇ is hydrophobic.
  • This motif forms a helix which binds a conserved surface of hydrophobic residues on the dorsal side of eIF4E (FIGURE 5A).
  • the 4E-BPs also contain this motif and compete with eIF4G for available eIF4E.
  • Hierarchical phosphorylation of the 4E-BPs controls their activity: hypophosphorylated 4E-BPs bind to eIF4E with full affinity while hyperphosphorylated states have greatly reduced affinity. This level of phosphorylation thus acts as a switch which increases the level of eIF4E available to form translationally active eIF4F complexes in response to extracellular stimuli such as nutrients and growth factors.
  • These signals are primarily transduced through the PBK/Akt pathway to activate the kinase mTOR, which phosphorylates 4E-BPs both directly and possibly indirectly through the action of downstream mTOR-dependent kinases.
  • eIF4F complexes The disruption of proper translational regulation by elevated levels of eIF4F complexes is an important factor in carcinogenesis.
  • a wide variety of tumors have been found to have .
  • abnormally elevated eIF4E levels, and eIF4G is amplified in some lung cancers.
  • the overexpression of eIF4E in cultured cells can cause them to exhibit a malignant transformed phenotype: rapid proliferation, loss of contact inhibition, and anchorage-independent growth.
  • This transformation is dependent on eIF4E's ability to bind eIF4G, as co-expression of 4E-BP1 in these cells can partially reverse their malignant properties.Elevated eIF4E levels are detected in cancers of the breast, head, neck, bladder, colon, prostate, gastrointestinal tract and lung, Hodgkin's lymphomas, and neuroblastomas. In breast cancer patients, the risk of cancer recurrence and cancer-related death is correlated with the level of eIF4E overexpression. The other components of eIF4F are overexpressed in specific types of cancer: eIF4G in squamous cell lung carcinomas, and eIF4A in melanomas and primary hepatocellular carcinomas.
  • Loss of proper regulation of the eIF4E-eIF4G interaction plays an important role in the development of many cancers.
  • the protein-protein interaction between eIF4E and eIF4G is an essential step in cap-dependent translation initiation. Because the translation of the mRNAs encoding most proteins involved in cellular growth and proliferation is highly cap-dependent, regulation of the level of complex formation between eIF4E and eIF4G plays an important role in the control of these processes.
  • the interaction between these proteins is inhibited by the 4E binding proteins (4E-BPs), which compete with eIF4G for binding to the same surface on eIF4E. Phosphorylation of specific sites on 4E-BPs in response to growth and proliferation signals inhibits their ability to bind eIF4E.
  • the level of eIF4E/eIF4G complex formation also plays a role in the control of apoptosis.
  • 4E-BP1 has been found to undergo a caspase cleavage of its N-terminus which removes a motif necessary for it to undergo phosphorylation, leading to increased 4E-BP1 binding to eIF4E and inhibition of cap-dependent translation. This inhibition causes a shift in the levels of pro and anti apopoptic proteins to favor apoptosis.
  • Experiments in cultured cells have shown that peptides containing the eIF4E recognition motif of eIF4G fused to a penetratin sequence can induce apoptosis.
  • Chemical library synthesis and fluorescence assay technologies were used to identify small molecule inhibitors of protein-protein interactions by screening large numbers of compounds. These compounds provide tools for "reverse chemical genetics", in which a small molecule which selectively regulates the activity of a protein is used to elucideat its role in biological processes.
  • a chemical inhibitor of the eIF4E/eIF4G interaction specifically inhibits cap-dependent translation, and inhibits tumor growth and progression in tumor types that are characterized by eIF4E or eIF4G overexpression.
  • the fusion protein GBl-meIF4E was constructed by cloning the full coding sequence of murine eIF4E into a GBl expression vector using the BamHI and EcoRI sites. Both tagged and native eIF4E was expressed in E. coli using standard methods and purified using affinity chromatography on m7GDP or m7GTP agarose resin.
  • the C-terminal fluorescein labeled peptide has sequence KYTYDELFQLK (SEQ ID NO:2) and was synthesized by Research Genetics using standard methods. This sequence contains the Y(X) 4 LO motif and was optimized for solubility and binding to eIF4E.
  • the unlabeled competitor eIF4GII peptide has the sequence KKQYDREFLLDFQFMPA (SEQ ID NO:3) and was synthesized by Tufts University Core Facility using standard methods. For screening and subsequent peptide binding assays measurements of fluorescence polarization were made using an LJL Analyst plate reader.
  • All protein samples for NMR were in a buffer composed of 50 mM sodium phosphate, 50 mM potassium chloride, and 2 mM DTT at pH 6.5.
  • DTT concentration was increased to 20 mM.
  • the Standard three pairs of triple resonance experiments were recorded: HNCA/HN(CO)CA, HNC0/HN(CA)C0, and HNCACB/HN(CO)CACB.
  • the HNCA/HN(CO)CA dataset was recollected using a higher protein concentration and TROSY versions of the experiments in order to get better sensitivity.
  • a dicistronic reporter construct containing the Renilla reniformis luciferase sequence after the 5' UTR followed by the CrPV IRES and the firefly luciferase sequence was used to build a reporter construct plasmid.
  • the reporter construct plasmid was linearized with BamHI and transcribed in vitro with an ARCA cap using the mMessage Machine T7 Ultra Kit (Ambion). In vitro translation reactions were carried out using Red Nova reticulocyte lysate (Novagen) with 2 mM magnesium acetate and 153 mm potassium acetate , incubated at 30 degrees C for 90 minutes. Translation of reporter genes was measured using the Dual-Glo luciferase assay (Promega) in a Wallac Victor 2 plate reader.
  • Adherent human solid tumor cells were plated and maintained for 3 days in the presence of increasing concentration of the compounds, and cell proliferation was measured by alamar blue assay, where 10% of commercially available solution is added to the cell medium and measure fluorescence in 96-well plates at wavelength of 530 nm excitation and 590 nm emission. The data calculations were carried out as previously described.
  • m 7 GTP pull-down assay For the in vitro version of the assay, aliquots of Red Nova reticulocyte lysate with the same salt and buffer concentrations as in the translation reactions were incubated with compound or 200 ⁇ M m 7 GDP) for 1 hour at 37 degrees C. Following incubation the lysate was incubated with m 7 GTP-Sepharose beads for 1 hour at 4 degrees C. After extensive washing bound proteins were eluted with free m 7 GTP, resolved by SDS-PAGE, and subjected to Western blotting using a polyclonal antibody against 4E-BP1 (Cell Signaling Technology), and monoclonal antibodies against eIF4E and eIF4G (Transduction Laboratories).
  • 4E-BP1 Cell Signaling Technology
  • Jurkat cells were grown for 6 hours in the presence of the compound, harvested by centrifugation, and lysed by multiple freeze-thaw cycles. Extracts prepared by this method were analyzed using the same pull-down protocol as with the reticulocyte lysates.
  • Jurkat cells were grown for 8 hours in the presence of the compound. Extracts for Western blotting were prepared from half of the cells by multiple freeze-thaw cycles, ⁇ -actin, Bcl-xL, and c-myc were detected using polyclonal antibodies (Cell Signaling). For the remaining cells the PARIS kit (Ambion) was used to isolate total nuclear and total cytoplasmic RNA fractions. The integrity of the fractionation was confirmed by agarose gel electrophoresis (as prescribed by Ambion). Contaminating DNA was removed using the DNA-free kit (Ambion), and cDNA was prepared using MMLV reverse transcriptase (Promega).
  • the relative abundance of the c-myc and Bcl-xL messages compared to ⁇ -actin was determined by real-time PCR with validated QuantiTec probes and the QuantiTec SYBR Green Kit (Qiagen), using a thermocycler from Applied Biosystems.
  • a lung cancer cell line, A549 was used in a proliferation assay known in the art, e.g., Fan et al. Bioorg. Med. Chem. Lett. 14: 2547-50, 2004.
  • the cytotoxicity assaying was carried out by incubating plated cells in the presence of compound for 16 hours and determining cell viability using the CellTiter-Glo luminescence cell assay (Promega).
  • EGI-I was determined using the SRB staining method as previously described.
  • a fluorescence polarization (FP) assay was developed to measure binding of a peptide containing the conserved eIF4E-binding motif to eIF4E.
  • the peptide is conjugated to fluorescein at its carboxyl terminus, and when titrated with purified eIF4E its fluoresence polarization, increases almost three-fold as the fraction of bound labeled peptide increases.
  • a competitor unlabeled eIF4G peptide is added to the mixture of labeled peptide and eIF4E the FP goes down to the basal level observed with the free peptide (FIGURE 5B).
  • This system thus provided a simple and sensitive assay for detecting small molecules which can disrupt the protein-protein interaction between eIF4E and eIF4G by competitively binding to the same conserved hydrophobic surface as the consensus peptide.
  • the assay was adapted to a microwell plate format and used to screen a number of libraries comprised of small molecule libraries for potential eIF4E/eIF4G interaction inhibitors. Because screens for inhibitors of protein-protein interactions typically have very low hit rates (on the order of .01-.l%), the strategy taken was to carry out a large initial screen comprising the Chembridge Diverset E library (16,000 compounds), the Bionet library (4,800), the Maybridge library (8,800), the Peakdale library (2,816), and a portion of the Chembridge Microformat library for a total of 42,416 compounds. Two hit compounds with drug-like structures were selected from this screen for further characterization: EGI-I (compound 154300) and 6006288 (FIGURE 5C). Fig.
  • ID shows inhibition of labeled peptide binding for these two compounds: by comparison of the potency of inhibition to that of an eIF4G peptide of known binding affinity the affinities of these compounds are estimated at 1 uM for EGI-I (compound 154300) and 10 uM for 6006288.
  • solubility was improved by constructing a fusion of this protein with the 56-residue GBl domain of protein G. This domain has been found to act as a solubility enhancement tag for heterologous proteins to which it is fused. This construct has dramatically improved solubility and stability, and inspection of the HSQC spectra of the native and fusion proteins shows that the presence of this tag does not have any affect on the native structure of eIF4E.
  • the information on the site of compound binding acquired by NMR provides a basis for modeling the binding of these molecules to eIF4E using computational methods.
  • the program TreeDock (A. Fahmy, G. Wagner: TreeDock: A Tool for Protein Docking Based on Minimizing van der Waals Energys, J. Am. Chem. Soc, 124, 1241-1250 (2002)), predicts favorable conformations of a protein bound to a ligand by exhaustively docking the ligand in all possible orientations and using calculations of the Lennard- Jones potential to evaluate the free energy.
  • the binding of EGI-I (compound 154300) was modeled by running a TreeDock calculation with the compound restricted to being proximal to Ser82 and Ser83. This predicts that this compound can bind to the surface of eIF4E in a conformation that blocks the eIF4G peptide from binding.
  • a representative low energy structure is shown in FIGURE 7C.
  • EGI-I compound 154300
  • FGI-I compound 154300
  • FIG. 8A IC50 of approximately 6 uM
  • FIG. 8B a luminescence assay
  • No significant cytotoxicity is observed in the range of concentrations where EGI-I (compound 154300) has anti-proliferative activity. These data indicate that this compound inhibits growth and proliferation of tumor cells. Additional compounds were also tested. Fluorescence polarization data is shown below in Table 1.
  • IC 50 was measured by fluorescent polarization assay. The values indicate the average concentration needed to inhibit 50 % of ceIF4E/EIF 4 G interaction. The experiments were done in triplicate with SD ⁇ +10%., using eIE4GII peptide and DMSO as the positive and negative controls, respectively.
  • GI 50 was measured using sulforhodamine B assay. The values indicate the average concentration needed to inhibit 50% of cell proliferation. The experiments were done in triplicate with SD ⁇ +10%, Using CLT and DMSO as the positive and negative controls, respectively.
  • Certain classes or types of tumors are characterized by overexpression of eIF4e or overexpression of eIF4G.
  • Inhibitory compounds that preferentially inhibit of cap-dependent translation compared to cap-independent translation are useful to inhibit growth and progression of those classes or tumor types in which eIF4e or eIF4G are overexpressed (compared to normal non-cancerous cells of the same tissue type).
  • Small molecule inhibitors of the eIF4E/eIF4G interaction were identified as described above.
  • EGI-I compound 154300
  • EGI-I compound 154300
  • the data described herein indicates the compounds described above are therapeutically useful to inhibit proliferation of tumors in which eIF4E or eIF4G is overexpressed.
  • antisense RNA to lower levels of eIF4E has been shown to suppress the tumorigenic and angiogenic properties of a head and neck squamous cell carcinoma cell line.
  • Analogs of rapamycin which act by inhibiting mTOR kinase, reducing 4E-BP phosphorylation, and thus decreasing the amount of free eIF4E, have been tested.
  • Example 1 NMR-Derived Structure-Based Design and Synthesis 2-Thiazolyl Hydrazones as inhibitiors of eIF4E/eIF4G Interaction
  • Eukaryotic initiation factor 4E is a highly conserved 25 kDa cap-binding protein. eIF4E binds to both the 5 '-end of mRNA-cap and eIF4G thereby bringing together these two molecules 1 .
  • eIF4G is a large master scaffolding protein that directly interacts with eIF4E, and eIF4A, an RNA-dependent ATPase that acts also as a helicase to unwind the secondary structure of the 5' untranslated region, to form the eIF4F complex.
  • hypophosphorylated eIF4E-binding protein (4E-BP) competes with eIF4G for binding to eIF4E and thereby acts as the physiological inhibitor of the eIF4E/eIF4G interaction that restricts formation of the eIF4F complex. Phosphorylation of 4E-BP releases eIF4E enabling formation of the eIF4F complex, a key regulator of translation initiation.
  • Translation initiation plays a critical role in the control of cell proliferation, malignant transformation and maintenance of transformed phenotypes. This is because mRNAs encoding for many oncogenic proteins and growth factors have highly structured 5'UTR that make their translation highly dependent on the helicase activity of the eIF4F complex. Consistently, over-expression of eIF4E in normal cultured cells causes malignant transformation, while inhibition of either eIF4E expression or the eIF4E/eIF4G interaction reverses the malignant phenotype in vitro and in vivo. For these reasons, small molecule inhibitors of translation initiation that mimic 4E-BP in preventing formation of the eIF4F complex are promising candidates for the development of novel target specific cancer therapy.
  • a hydrophobic patch comprised of V69, W73, Y76, L131, L135 and 1138 could serve as a hot spot for interacting with a complementary eIF4E binding hydrophobic surface in eIF4G and 4E-BP ( Figure 32).
  • the binding site of the lead compound 1 on eIF4E was identified from chemical shift mapping using the 15 N- 1 H HSQC analysis of the eIF4E in the absence and presence of the small molecule inhibitor. Residues 181, S82 and S83, whose signals were shifted the most, were identified as comprising the main interaction site between the inhibitor and the eIF4E protein. These residues are adjacent to the putative hot spot that binds the eIF4G-derived peptide. This information was used as restraints in the computational modeling of the structure of eIF4E/inhibitor complex. The TreeDock software was used for docking experiments.
  • the program exhaustively searched all possible docked conformations of the inhibitor and interaction sites at the protein surface, evaluated the binding energy based on the Lennard- Jones and hydrogen bond potentials, and identified those arrangements that are most energetically favorable and consistent with the chemical shift mapping data.
  • the results indicate that inhibitor 1 partially overlaps with the binding site for eIF4G (FIGURE 33A).
  • the simulated interaction between the inhibitor and specific amino acid residues in eIF4E is presented in FIGURE 33B. This model suggests that the binding orientation of the inhibitor to eIF4E is determined through a salt bridge formation between the carboxyl moiety of the inhibitor and the imidazole NH of H78 (4.3A), and a hydrogen bond with D77.
  • the 3,4- dichlorophenyl ring is positioned to form a ⁇ - ⁇ interaction with the indole moiety of the W73 residue located at the center of the putative hot spot that is reportedly essential for the eIF4E/eIF4G binding interaction.
  • a fluorescence polarization (FP) assay was used to measure binding to eIF4E by competing with a fluorogenic eIF4G-derived peptide containing the conserved eIF4E-binding motif (KRYDREFLLGF). Displacement of N ⁇ -fluorescein tagged eIF4G-derived peptide by a competing ligand causes a large decrease in fluorescence polarization.
  • a functional cell free assay determined the relative effects of the compounds on cap- and IRES-dependent translations.
  • This assay involved the in vitro translation of bicistronic mRNA reporter construct encoding for renilla luciferase in a cap-dependent and for firefly luciferase in a cap independent manner, the later driven by cricket paralysis virus IRES. Analysis of translation activity included subsequent incubations with firefly- and renilla luciferase substrates to determine the relative luminesemce vs. control.
  • cap-dependent mRNA was inhibited by inhibitors of eIF4E/eIF4G interaction, while translatio from the IRES was paradoxically enhanced, presumably due to increased availability of ribosomc as cap-dependent translation is inhibited).
  • a molecular model of eIF4E-hit compound 1 interface was utilized for structure-based design of eIF4E-eIF4G inihbitors. This model incorporated constraints generated by chemical shift mapping to enable the docking of the small molecule into the binding site of eIF4E.
  • Step 1 4-(3,4-Dichloro-phenyl)-thiazol-2-yI-hydrazine.
  • Step 2 2- ⁇ [4-(3,4-Dichloro-phenyl)-thiazoI-2-yI]-hydrazono ⁇ -3-(2-nitrophenyI)-propionic acid.
  • TreeDock module was implemented as a C-program on a single SGI RlOk workstation.
  • the input to TreeDock consists of PDB-files for the molecule, employing the coordinates of each atom in a PDB file we identified the solvent accessible surface.
  • the output of TreeDock is stored in two files: one contains the coordinates of the complex and another (optional) records Lennard- Jones energy contribution of all chemical moieties in the accessible surface. Parameters for the Lennard- Jones potential were obtained from the X-PLOR program.
  • eIF4F translation initiation complex eIF4F
  • eIF4F consists of the RNA helicase eIF4A, the docking protein eIF4G and the cap binding protein eIF4E
  • eIF4E is the major target for regulation by eIF4E-binding proteins (eIF4E-PBs).
  • eIF4E is released from a translationally inactive complex with 4E-BPs upon hypophosphorylation in response to stimulation by insulin and growth factors.
  • eIF4E-BPs dissociate from the complex with eIF4E and allow it to form an active translation initiation complex eIF4F.
  • mRNAs of growth- promoting proteins and oncogene products have often long 5'UTRs and their translation depends crucially on the interaction of the eIF4E/eIF4G interaction in a cap-dependent fashion.
  • many housekeeping proteins and pro-apoptotic proteins are translated in 2a cap- independent fashion through internal ribosomal entry sites (IRES-dependent way).
  • Inhibitors of the eIF4E/eIF4G interaction prevent formation of eIF4F complex would predominantly inhibit translation of mRNAs involved in tumor growth and survival and to have anti-tumor activity.
  • 2-Phenyl-5-hydrazineo-l,3,4-thiadiazole (2k) were obtained by diazotization of 2-amino-5- phenyl-l,3,4-thiadiazoles in hydrochloric acid with copper catalysis followed by treatment with hydrazine hydrate.
  • the final product (4k) was synthesized by condensation with D-keto acid.
  • 3- Phenyl-2-[(6-phenyl-pyridazin-3-yl)-hydrazono]-propionic acid (41) was synthesized by a similar fashion.
  • ICeo was measured by fluorescent polarization aasay. The values indicate the average concentration needed to inhibit 50% of ceIF4E/EIF4G interaction. The experiments were done in triplicate with SD ⁇ +10%., using eIE4GII peptide and DMSO as the positive and negative controls, respectively. b) Gl ⁇ o was measured using sulforhodamine B assay. The values indicate the average concentration needed to inhibit 50% of cell proliferation. The experiments were done in triplicate with SD ⁇ +10%, Using CLT and DMSO as the positive and negative controls, respectively.
  • the configurational isomers differ in the biological activity (Table 1). From a limited SAR study we have shown thatZ-2- ⁇ [(4,5-diphenyl)-thiazol-2-yl]-hydrazono ⁇ -3- phenyl)-propionic acid is two-fold more potent than its E isomer. In the eIF4E/4G assay, this compound is one order of magnitude more potent that the initial hit (Table 1). In addition, modifications made to the carboxyl and imine functions suggest that these are important structural features for bioactivity.
  • the eIF4E/eIF4G interaction represents the first molecular target for which we have a preliminary comparison of NMR spectra in the presence and absence of ligand. From these NMR studies we were able to identify partially overlapping interaction sites for both lead compounds.
  • ZIE isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05%HOAc in acetonitrile 50% : 0.05%HOAc in water 50% to 0.05%HOAc in acetonitrile 75% : 0.05%HOAc in water 25% in 20 min.
  • ZJE isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitril 50%: 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05% NH 4 OAc in water 25% in 30 min.
  • TJE isomer was further separated by HPLC-MS, using gradient eluting solvents: 0.05% NH 4 OAc in acetonitril 50%: 0.05% NH 4 OAc in water 50% to 0.05% NH 4 OAc in acetonitrile 75% : 0.05%
  • the product was purified by HPLC-MS, with a C 8 column, using gradient eluting solvents:
  • the product was purified by HPLC-MS, with a Cg column, using gradient eluting solvents: 0.1%
  • the product was purified by HPLC-MS 3 with a C 18 column, using gradient eluting solvents: 0.1% AcOH in acetonitrile 30%: 0.1% AcOH in water 70% to 0.1% AcOH in acetonitrile 60%: 0.1% AcOH in water 40% in 30 min.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

L'invention porte sur une composition et sur un procédé qui permettent d'inhiber la prolifération d'une cellule tumorale par comparaison avec une cellule non tumorale. L'invention concerne également des procédés de criblage d'une composition qui inhibe la traduction dépendante de la coiffe par comparaison avec la traduction indépendante de la coiffe des protéines.
EP06719064.5A 2005-01-21 2006-01-20 Regulation de la synthese des proteines par inhibition de l'interaction eif4e-eif4g Active EP1868604B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64621905P 2005-01-21 2005-01-21
PCT/US2006/002093 WO2006078942A2 (fr) 2005-01-21 2006-01-20 Regulation de la synthese des proteines

Publications (2)

Publication Number Publication Date
EP1868604A2 true EP1868604A2 (fr) 2007-12-26
EP1868604B1 EP1868604B1 (fr) 2014-08-13

Family

ID=36644936

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06719064.5A Active EP1868604B1 (fr) 2005-01-21 2006-01-20 Regulation de la synthese des proteines par inhibition de l'interaction eif4e-eif4g

Country Status (6)

Country Link
US (1) US8257931B2 (fr)
EP (1) EP1868604B1 (fr)
JP (1) JP5225691B2 (fr)
AU (1) AU2006206286B2 (fr)
CA (1) CA2619153C (fr)
WO (1) WO2006078942A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010066682A1 (fr) * 2008-12-08 2010-06-17 Euroscreen S.A. Composés, composition pharmaceutique et méthodes pour application au traitement de troubles métaboliques
WO2012006068A2 (fr) 2010-06-28 2012-01-12 President And Fellows Of Harvard College Composés pour inhiber la prolifération cellulaire
HU1000676D0 (en) 2010-12-17 2011-02-28 Pharmahungary 2000 Kft Inhibitors of matrix metalloproteinase, pharmaceutical compositions thereof and use of them for preventing and treating diseases where the activation of mmp is involved
US9073881B2 (en) 2011-09-23 2015-07-07 Hoffmann-La Roche Inc. Benzoic acid derivatives
CN104411715A (zh) * 2012-07-09 2015-03-11 霍夫曼-拉罗奇有限公司 靶向eIF4E的细胞穿透肽
JP2015534990A (ja) * 2012-10-22 2015-12-07 イージェニックス インコーポレイテッド 誤制御されたｅＩＦ４Ｅに関連する疾患又は障害を治療又は予防するための組成物及び方法
WO2014170786A1 (fr) 2013-04-17 2014-10-23 Pfizer Inc. Dérivés de n-pipéridin-3-ylbenzamide dans le traitement des maladies cardiovasculaires
GB201405991D0 (en) * 2014-04-03 2014-05-21 Cambridge Entpr Ltd Novel compounds
CN105541827B (zh) * 2016-02-16 2018-01-19 湖南大学 苄亚肼基噻唑基甲基喹啉酮衍生物及其作为抗癌药的应用
AU2017292646A1 (en) 2016-07-05 2019-02-07 Blade Therapeutics, Inc. Calpain modulators and therapeutic uses thereof
CA3038331A1 (fr) 2016-09-28 2018-04-05 Blade Therapeutics, Inc. Modulateurs de calpain et leurs utilisations therapeutiques
US10351609B2 (en) * 2016-12-12 2019-07-16 Medical Diagnostic Laboratories, Llc Cell-based assay for determining mTOR activity
CN107118177A (zh) * 2017-07-03 2017-09-01 南京林业大学 一类诺蒎酮噻唑腙衍生物及其制备方法和应用
FI3919486T3 (fi) 2018-04-25 2023-08-23 Bayer Ag Uusia heteroaryylitriatsoli- ja heteroaryylitetratsoliyhdisteitä torjunta-aineina
CN110938649A (zh) * 2018-09-25 2020-03-31 康码（上海）生物科技有限公司 一种提高外源蛋白表达量的蛋白合成体系及其应用方法
WO2020247819A2 (fr) * 2019-06-07 2020-12-10 Agios Pharmaceuticals, Inc. Méthode de traitement à l'aide de modulateurs de l'acide aminolévulinique synthase 2 (alas2)
TW202114681A (zh) 2019-07-02 2021-04-16 美商ｅＦＦＥＣＴＯＲ醫療公司 轉譯抑制劑及其用途
KR20220164706A (ko) 2020-03-03 2022-12-13 피아이씨 테라퓨틱스 인코포레이티드 Eif4e 억제제 및 이의 용도

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6503914B1 (en) * 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20050004134A1 (en) * 2001-11-08 2005-01-06 Hideo Tsutsumi Thiazole derivative and pharmaceutical use thereof
JP2003313168A (ja) 2002-04-18 2003-11-06 Kirin Brewery Co Ltd Ｂｃｌ−２阻害活性を有する化合物およびその化合物のスクリーニング方法
DE602004025708D1 (de) * 2003-07-11 2010-04-08 Proteologics Inc Ubiquitin-ligase-hemmer und verwandte verfahren

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2006078942A2 *

Also Published As

Publication number Publication date
CA2619153A1 (fr) 2006-07-27
CA2619153C (fr) 2013-12-31
US20100144805A1 (en) 2010-06-10
AU2006206286A1 (en) 2006-07-27
WO2006078942A2 (fr) 2006-07-27
AU2006206286B2 (en) 2011-05-26
JP2008528502A (ja) 2008-07-31
US8257931B2 (en) 2012-09-04
WO2006078942A3 (fr) 2007-04-19
JP5225691B2 (ja) 2013-07-03
EP1868604B1 (fr) 2014-08-13

Similar Documents

Publication Publication Date Title
CA2619153C (fr) Regulation de la synthese des proteines
Barros et al. Synthesis and anti-inflammatory activity of new arylidene-thiazolidine-2, 4-diones as PPARγ ligands
ES2226785T3 (es) Derivados de fenilurea como antagonistas de los receptores de orexina.
AU2016203895B2 (en) Proteostasis regulators
JP5677719B2 (ja) ２，３置換ピラジンスルホンアミド
Küçükgüzel et al. Synthesis, characterization of novel coupling products and 4-arylhydrazono-2-pyrazoline-5-ones as potential antimycobacterial agents
Subasinghe et al. A novel series of pyrazolylpiperidine N-type calcium channel blockers
CA2922851A1 (fr) Modulateur des canaux sodiques pour le traitement de la douleur et du diabete
JP2008540537A (ja) チアゾール化合物および使用方法
WO2015051149A1 (fr) Analogues de sorafenib et leurs utilisations
AU2014240003B2 (en) Coumarin derivatives and methods of use in treating hyperproliferative diseases
BR0309892A2 (pt) composto, composição, métodos para modular a atividade da cinesina de ksp, para inibir a ksp, e para o tratamento de uma doença proliferativa celular, e, uso de um composto
US10323004B2 (en) Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
CN108473426A (zh) 环状胺衍生物和其医药用途
EA025356B1 (ru) Антагонисты trpm8
Gege et al. Identification and biological evaluation of thiazole-based inverse agonists of RORγt
Tian et al. Discovery of N-indanyl benzamides as potent RORγt inverse agonists
JP2014520899A (ja) 小分子によるヒト癌におけるｇｌｉタンパク質の標的化
Qiu et al. Design, synthesis and evaluation of novel phenyl propionamide derivatives as non-nucleoside hepatitis B virus inhibitors
US20130203709A1 (en) Acylsulfonamides and processes for producing the same
JP2017527573A (ja) 糖尿病の治療用の選択的ＮａＶ１．７阻害剤
Wang et al. Design, synthesis and anticancer activity of 5-aryl-4-(4-arylpiperazine-1-carbonyl)-1, 2, 3-thiadiazoles as microtubule-destabilizing agents
US20190016680A1 (en) Mast-cell modulators and uses thereof
WO2022262657A1 (fr) Composé de phénylsulfonamide n-substitué et son utilisation
Lu et al. Development and therapeutic potential of allosteric retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonists for autoimmune diseases

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070820

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WAGNER, GERHARD

Inventor name: HALPERIN, JOSE

Inventor name: MOERKE, NATHAN, JOHN

Inventor name: AKTAS, HUSEYIN

Inventor name: CHOREV, MICHAEL

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20110117

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20140325

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 681746

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140815

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602006042669

Country of ref document: DE

Effective date: 20140925

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20140813

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 681746

Country of ref document: AT

Kind code of ref document: T

Effective date: 20140813

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141114

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141215

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141113

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20141213

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602006042669

Country of ref document: DE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

26N No opposition filed

Effective date: 20150515

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20150120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150131

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20150120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20060120

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20140813

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230505

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: DE

Payment date: 20240129

Year of fee payment: 19

Ref country code: GB

Payment date: 20240129

Year of fee payment: 19

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20240125

Year of fee payment: 19